At a glance
ClinicalIndex Comparison RecordEarly Ph 1Not Yet Recruiting· 12 target
Drug / intervention
CMTS0929biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
CMTS0929 for Clostridioides Difficile Infection: a Prospective, Open-label, Single-arm Clinical Study
The Second Hospital of Nanjing Medical University·interventional·Posted Feb 20, 2025·Updated Feb 20, 2025
In Brief
A Early Phase 1 clinical trial evaluating CMTS0929 for Clostridioides Difficile Infection. Not yet recruiting, targeting 12 participants across 1 site.
Detailed Summary
This is a prospective, open-label, single-arm study to explore the safety and the efficacy of CMTS0929 for patients with Clostridioides difficile infection (CDI).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsClostridioides Difficile Infection
CountriesChina
Collaborators--
Timeline
Early Ph 1Not Yet Recruiting
202520262027202820292030
First PostedFeb 2025
Enrollment StartFeb 2025
TodayJul 2026
Primary CompletionJan 2030
Study CompletionJul 2030
First PostedFeb 20, 2025
Enrollment StartFeb 20, 2025
Primary CompletionJan 31, 2030
Study CompletionJul 1, 2030
TodayJul 1, 2026
Enrollment to primary: 4.9 yearsPosted 1.4 years agoPrimary completion in 3.6 years
Interventions
CMTS0929biological
CMTS0929 is defined as suspension from washed microbiota.